Clario Acquires AI Company ArtiQ

Clario acquires artificial intelligence powered software company, ArtiQ

Overview

Clario, a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, announced the acquisition of the technology company ArtiQ. This acquisition expands the power of artificial intelligence (AI) in Clario’s Respiratory Solutions portfolio and enhances the company’s ability to further leverage and develop innovative uses of AI across its service lines.

Words from CEO: Clario

• We’re thrilled to welcome ArtiQ into our organization,” said Chris Fikry, chief executive officer at Clario. “Since 2018, Clario has been a pioneer in applying artificial intelligence to improve the quality and efficiency of clinical trial execution. This move significantly advances AI within our respiratory portfolio. With ArtiQ’s technology, we are expanding our ability to rapidly scale AI for overreading while ensuring data quality and streamlining the clinical trial process for patients worldwide.”
• In addition to continuing to lead ArtiQ, Marko Topalovic will step in to lead Clario’s overall AI strategy across the organization. Of the acquisition, he said: “Joining forces with Clario is a pivotal moment for ArtiQ. Our technology’s integration into Clario’s portfolio not only enhances the quality and efficiency of spirometry data analysis but also marks a sizable step toward minimizing the patient burden and improving trial outcomes. With Clario, our technology can scale worldwide to all clinical trials and sponsors, and we now have the chance to foster a positive impact beyond the scope of respiratory care.”

Other Acquisition

• In addition to the ArtiQ acquisition, Clario acquired Inofab Health, the manufacturer of easy- to-use ultrasonic sensor spirometer devices, in November 2023. 
• Bringing these acquisitions together with Clario’s deep respiratory scientific capabilities will strengthen Clario’s Respiratory Solutions portfolio, serve as a launchpad for advancing AI within clinical trials, and increase its reach into the broader healthcare market.

Words from CTO: Clario

We’re committed to pioneering AI models that help rapidly deliver high-quality data in clinical trials,” said Jay Ferro, Clario’s chief information, technology and product officer. “This acquisition reinforces that commitment and ensures we continue to make good on our mission to help our customers transform patient lives around the world.”

Clario

Clario is a leading healthcare research and technology company that generates better clinical evidence for our pharmaceutical, biotech, and medical device partners.

ArtiQ

ArtiQ, a spin-off from the Belgian university KU Leuven, is a leading innovative software company dedicated to enhancing the diagnosis and monitoring of patients with respiratory conditions.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!